Numerous scholars have indicated that prostate cancer cells with the CD133+/CD44+ phenotype demonstrate certain stem cell characteristics, including renewal, multi-potential differentiation, unlimited proliferative capacity and permanency (9–11). This evidence concerns the gene CD44 and prostate carcinoma.